Home » Newsletters » BioWorld Science

BioWorld Science

April 12, 2022

View Archived Issues

Cocktail of two human survivor antibodies protects NHPs from Ebola and Sudan virus diseases

Shanghai Hongheng Biomedical Technology divulges anticancer compounds

Janssen describes new Casein kinase I isoform delta inhibitors

New N-myristoyltransferase inhibitors presented by MyricX Pharma, Imperial Innovations Group

Zhejiang Hisun Pharmaceutical, Hisun Accuray Therapeutics patent anticoagulants

Phytos identifies new PD-L1 inhibitors

BCAT deletion from T cells may offer advantage to lymphoma immunotherapy

Inhibition of kininase I prevents angiotensin II-induced hypertension

IMP-2 validated as cancer target, small-molecule inhibitors identified

Targeting 5-HT1AR as novel therapeutic strategy for Fragile X syndrome

TLR9 inhibitor-loaded nanoparticles protect against radiation-induced BBB disruption

New small molecules synergize with ciprofloxacin against S. tiphy biofilms in the gallbladder

E-7011, a neutralizing antibody targeting Notch4 to inhibit tumor growth

Changes in the adaptive immunity of PD mice models carrying LRRK2 mutations drive neurodegeneration

Artiva and Merck & Co. agree to evaluate combinations of NK cells with trispecific NK-cell engagers

MJFF grant supports use of Lucy Therapeutics' mitochondrial platform to target Parkinson's disease

New approach enables systematic search for elusive allosteric binding sites on proteins

Captor's CT-01 compounds for HCC shown to induce degradation of GSPT1 and SALL4

Seed financing supports PolyCore's development of PCT-3012 for Parkinson's disease

SciRhom nominates anti-iRhom2 antibody as drug candidate for autoimmune diseases

BRD4-MK2 axis induces fibrosis in Crohn's disease

AAHI receives donation to support development of next-generation vaccine and therapeutic solutions

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...